Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PFE stock price vs WAT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at WAT's multiple
Needs WAT P/E.
Implied fair value · at PFE's multiple
Needs PFE P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
16 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
PFIZER INC · implied price per share
Bear
$10.17
Base
$12.82
Bull
$17.53
Waters Corporation · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
JOHNSON & JOHNSON
PFE vs JNJ
Merck & Co., Inc.
PFE vs MRK
AbbVie Inc.
PFE vs ABBV
BRISTOL MYERS SQUIBB CO
PFE vs BMY
ELI LILLY & Co
PFE vs LLY
AMGEN INC
PFE vs AMGN
DANAHER CORP /DE/
PFE vs DHR
AGILENT TECHNOLOGIES, INC.
PFE vs A
BIO-RAD LABORATORIES, INC.
PFE vs BIO
THERMO FISHER SCIENTIFIC INC.
PFE vs TMO
BRUKER CORP
PFE vs BRKR
BIO-TECHNE Corp
PFE vs TECH
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PFE can stabilize revenue and sustain its high gross margin while improving quality metrics, then the stock looks attractive versus WAT because the current price is well below WAT-implied valuation and near the low end of its own range.
PFE trades at 19.1x P/E versus WAT at 36.7x, and at 2.4x P/S versus 12.2x for WAT, indicating a large relative valuation discount on both earnings and sales bases. The implied price of $49.85 suggests 92.3% upside, but PFE is already near the low end of its historical and DCF ranges, which limits conviction in a simple rerating case.
Supporting Metrics
